These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 18338264)

  • 1. Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review.
    Koppisetti S; Jenigiri B; Terron MP; Tengattini S; Tamura H; Flores LJ; Tan DX; Reiter RJ
    Dig Dis Sci; 2008 Oct; 53(10):2592-603. PubMed ID: 18338264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.
    Wang HH; Portincasa P; Mendez-Sanchez N; Uribe M; Wang DQ
    Gastroenterology; 2008 Jun; 134(7):2101-10. PubMed ID: 18442485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for
    Wang HH; Portincasa P; Liu M; Tso P; Wang DQ
    Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of endoscopic sphincterotomy on gall bladder bile lithogenicity and motility.
    Sharma BC; Agarwal DK; Baijal SS; Negi TS; Choudhuri G; Saraswat VA
    Gut; 1998 Feb; 42(2):288-92. PubMed ID: 9536957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect.
    Portincasa P; Stolk MF; van Erpecum KJ; Palasciano G; van Berge-Henegouwen GP
    Scand J Gastroenterol Suppl; 1995; 212():63-78. PubMed ID: 8578234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: defects in gall-bladder motor function--role in gallstone formation and recurrence.
    Pauletzki J; Paumgartner G
    Aliment Pharmacol Ther; 2000 May; 14 Suppl 2():32-4. PubMed ID: 10903000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: low caloric intake and gall-bladder motor function.
    Festi D; Colecchia A; Larocca A; Villanova N; Mazzella G; Petroni ML; Romano F; Roda E
    Aliment Pharmacol Ther; 2000 May; 14 Suppl 2():51-3. PubMed ID: 10903004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: in vitro studies of gall-bladder smooth muscle function. Relevance in cholesterol gallstone disease.
    Portincasa P; Minerva F; Moschetta A; Venneman N; Vanberge-Henegouwen GP; Palasciano G
    Aliment Pharmacol Ther; 2000 May; 14 Suppl 2():19-26. PubMed ID: 10902998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous elevation of plasma cholecystokinin does not prevent gallstones.
    Shahid RA; Wang DQ; Fee BE; McCall SJ; Romac JM; Vigna SR; Liddle RA
    Eur J Clin Invest; 2015 Mar; 45(3):237-46. PubMed ID: 25641074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gallstones: an intestinal disease?
    Van Erpecum KJ; Van Berge-Henegouwen GP
    Gut; 1999 Mar; 44(3):435-8. PubMed ID: 10026334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the Molecular Mechanisms Underlying the Effect of Cholecystokinin and Cholecystokinin-1 Receptor on the Formation of Cholesterol Gallstones.
    Wang HH; Portincasa P; Wang DQ
    Curr Med Chem; 2019; 26(19):3407-3423. PubMed ID: 28625150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased incidence of biliary sludge and normal gall bladder contractility in patients with high spinal cord injury.
    Tandon RK; Jain RK; Garg PK
    Gut; 1997 Nov; 41(5):682-7. PubMed ID: 9414978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice.
    Wang DQ
    J Lipid Res; 2002 Nov; 43(11):1950-9. PubMed ID: 12401894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR.
    Moschetta A; Stolk MF; Rehfeld JF; Portincasa P; Slee PH; Koppeschaar HP; Van Erpecum KJ; Vanberge-Henegouwen GP
    Aliment Pharmacol Ther; 2001 Feb; 15(2):181-5. PubMed ID: 11148435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gallstones and gall bladder carcinoma.
    Vitetta L; Sali A; Little P; Mrazek L
    Aust N Z J Surg; 2000 Sep; 70(9):667-73. PubMed ID: 10976897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasonographic assessment of gall bladder kinetics in the elderly.
    Rajan M; Wali JP; Sharma MP; Dhar A; Aggarwal P
    Indian J Gastroenterol; 2000; 19(4):158-60. PubMed ID: 11059179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical and metabolic factors in gallstone pathogenesis.
    Donovan JM
    Gastroenterol Clin North Am; 1999 Mar; 28(1):75-97. PubMed ID: 10198779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease.
    Cariati A; Piromalli E
    Expert Opin Pharmacother; 2012 Jun; 13(9):1223-7. PubMed ID: 22607008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs affecting biliary lipid secretion and gallbladder motility: their potential role in gallstone treatment and prevention.
    vanBerge-Henegouwen GP; Venneman NG; van Erpecum KJ; Portincasa P
    Curr Drug Targets Immune Endocr Metabol Disord; 2005 Jun; 5(2):185-91. PubMed ID: 16089351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.
    Wang HH; Portincasa P; Wang DQ
    Eur J Clin Invest; 2016 Feb; 46(2):158-69. PubMed ID: 26683129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.